No Image Provided

SolasCure

VC Funding

Series B Angel-backed

Healthcare & Biotech Published 27 March 2023

Summary

In a significant market movement during March 2023, SolasCure was the subject of a vc funding. The transaction achieved a gross valuation of £10,900,000. Leading the round was Jonathan Milner, BRAIN Biotech, EVA Pharma, Wealth Club, Seneca Partners.

This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.

Lead Investor / Acquirer

Jonathan Milner

Lead Investor / Acquirer

BRAIN Biotech

Lead Investor / Acquirer

EVA Pharma

Lead Investor / Acquirer

Wealth Club

Lead Investor / Acquirer

Seneca Partners

Advising Broker

Undisclosed Firm

Related Deals in Healthcare & Biotech

Series B prioritised

VC Funding

Evaro

£18,000,000

Jan 2026

VC Funding

Kraken Technologies

£25,000,000

Jan 2026

VC Funding

Scan.com

£67,220,000

Sept 2026

VC Funding

Ternary Therapeutics

£3,600,000

Mar 2026

View Company Details

Financials, officers, full deal history

Original Source

This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.

View on Tech.eu Funding Explorer

Funding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Free to all registered users.